Table 3. Quality of care parameters.
| Baseline (n= 353) | Last visit (n= 353) | P-value | |
|---|---|---|---|
| Systolic blood pressure (mm Hg) | 146±30 | 137±30 | 0.0001 |
| Diastolic blood pressure (mm Hg) | 79 ±14 | 71±15 | 0.0001 |
| MAP mm Hg | 101±18 | 94±18 | 0.0001 |
| SystBP⩾140 mm Hg or diastBP⩾90 mm Hg | 197 (56.3) | 162 (46.4) | 0.01 |
| Blood pressure <130/80 mm Hg (%) | 81 (23.1) | 132(37.8) | 0.0001 |
| HTN on treatment (%) | 182 (91.5) | 199 (100) | 0.0001 |
| HTN treatment and controlled (%) | 26 (14.4) | 62 (31.5) | 0.0001 |
| BMI (kg/m2) | 26.0±5.1 | 25.8±5.4 | 0.17 |
| Hemoglobin (g/dl) | 11.8±1.9 | 11.8±1.8 | 0.98 |
| <11 g/dl (%) | 96 (27.7) | 104 (30.0) | 0.57 |
| Blood glucose (mg/dl)a | 149±78 | 130±73 | 0.005 |
| ⩽130 mg/dl (%)a | 114 (50.4) | 153 (67.7) | 0.0001 |
| HgbA1c (%)a | 8.5±2.0 | 7.8±1.6 | 0.03 |
| <7.0 (%) | 20 (25.6) | 27(31.4) | 0.52 |
| Total cholesterol (mg/dl) | 188±59 | 178±53 | 0.003 |
| >160 mg/dl (%) | 182 (64.8) | 190 (60.3) | 0.30 |
| Triglycerides (mg/dl) | 187±130 | 174±115 | 0.11 |
| >500 mg/dl (%) | 5 (1.8) | 10 (3.1) | 0.44 |
| Serum uric acid (mg/dl) | 6.88±2.06 | 6.43±1.92 | 0.001 |
| Hyperuricemia (%)b | 150 (46.3) | 120 (37.0) | 0.02 |
| Serum albumin (g/dl) | 3.5±0.6 | 3.5±0.7 | 0.37 |
| Serum calcium (mg(dl) | 8.9±0.9 | 8.9±0.7 | 0.46 |
| Within normal range (%) | 169 (76.8) | 218 (80.1) | 0.43 |
| <8.4 mg/dl | 46 (20.9) | 48 (17.6) | 0.42 |
| Serum phosphate (mg/dl) | 4.3±0.8 | 4.4±1.0 | 0.74 |
| Within normal range | 125 (67.2) | 166(65.1) | 0.72 |
| >4.6 mg/dl | 57 (30.6) | 82 (33.3) | 0.81 |
| Serum creatinine (mg/dl) | 2.29±0.86 | 2.8±1.70 | 0.000 |
| eGFR (ml/min per 1.73 m2)c | 32.4±13.0 | 32.4±17.0 | 0.43 |
| eGFR (ml/min per 1.73 m2)a | 31.3±11.3 | 27.5±15.3 | 0.000 |
| Proteinuria non-DM (%) | 54 (47.8) | 54 (45.8) | 0.86 |
| Proteinuria DM | 117 (55.7) | 122 (56.2) | 0.99 |
| Insulin use (%)a | 147 (65.0) | 168 (74.3) | 0.02 |
| Oral hypoglycemics use (%)a | 38 (16.8) | 39 (17.3) | 0.89 |
| ACEI use (%) | 243 (68.8) | 232 (66.3) | 0.52 |
| ARB use (%) | 108 (30.6) | 163 (46.6) | 0.001 |
| Beta blockers use (%) | 39 (11.0) | 67 (19.0) | 0.003 |
| Aspirin use (%) | 94 (26.7) | 91 (26.0) | 0.89 |
| Statin use (%) | 146 (41.4) | 281 (80.3) | 0.001 |
| Allopurinol use (%) | 73 (20.7) | 221 (63.1) | 0.001 |
| EPO use (%) | 37 (10.5) | 82 (23.4) | 0.001 |
| Calcitriol use (%) | 10 (2.8) | 6 (1.7) | 0.41 |
| Calcium binders (%) | 148 (41.9) | 289 (82.6) | 0.001 |
Abbreviations: ACEI, ACE inhibitor; ARB, angiotensin II receptor blockers; BMI, body mass index; BP, blood pressure; diastBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration; EPO, erythropoietin; MAP, mean arterial blood pressure; systBP, systolic blood pressure.
a
Diabetic patients only.
b
Nondiabetic patients.
c
>6.5 mg/dl in females and >7.5 mg/dl in males.